iX Biopharma Ltd. (SGX:42C)
0.4550
0.00 (0.00%)
At close: Nov 18, 2026
iX Biopharma Revenue
iX Biopharma had revenue of 2.71M SGD in the quarter ending September 30, 2026, with 70.58% growth. This brings the company's total for the last twelve months to 7.96M, up 6.17% year-over-year. In the fiscal year ending June 30, 2026, iX Biopharma had annual revenue of 6.85M, down -11.77%. That makes iX Biopharma the 39,302nd largest company in the world by revenue and 473rd in Singapore.
Revenue (ttm)
7.96M
Revenue Growth
+6.17%
P/S Ratio
62.49
Revenue / Employee
215.16K
Employees
37
Market Cap
497.46M
Revenue by Segment
Fiscal year ended Jun 30, 2026 See the full iX Biopharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 6.85M | -914.00K | -11.77% |
| Jun 30, 2025 | 7.77M | 1.81M | 30.34% |
| Jun 30, 2024 | 5.96M | 46.00K | 0.78% |
| Jun 30, 2023 | 5.91M | -8.48M | -58.91% |
| Jun 30, 2022 | 14.39M | 12.65M | 724.64% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kimly | 324.18M |
| Jumbo Group | 198.01M |
| CNMC Goldmine Holdings | 182.11M |
| OUE Healthcare | 152.51M |
| Resources Global Development | 140.19M |
| Old Chang Kee | 106.09M |
| Lum Chang Creations | 101.57M |
| ISEC Healthcare | 83.67M |